PT  - JOURNAL ARTICLE
AU  - Liu, Zhuoming
AU  - VanBlargan, Laura A.
AU  - Rothlauf, Paul W.
AU  - Bloyet, Louis-Marie
AU  - Chen, Rita E.
AU  - Stumpf, Spencer
AU  - Zhao, Haiyan
AU  - Errico, John M.
AU  - Theel, Elitza S.
AU  - Ellebedy, Ali H.
AU  - Fremont, Daved H.
AU  - Diamond, Michael S.
AU  - Whelan, Sean P. J.
TI  - Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
AID  - 10.1101/2020.11.06.372037
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.11.06.372037
4099  - http://biorxiv.org/content/early/2020/11/08/2020.11.06.372037.short
4100  - http://biorxiv.org/content/early/2020/11/08/2020.11.06.372037.full
AB  - Although neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of most COVID-19 vaccines and being developed as therapeutics, escape mutations could compromise such countermeasures. To define the immune-mediated mutational landscape in S protein, we used a VSV-eGFP-SARS-CoV-2-S chimeric virus and 19 neutralizing monoclonal antibodies (mAbs) against the receptor binding domain (RBD) to generate 48 escape mutants. These variants were mapped onto the RBD structure and evaluated for cross-resistance by convalescent human plasma. Although each mAb had unique resistance profiles, many shared residues within an epitope, as several variants were resistant to multiple mAbs. Remarkably, we identified mutants that escaped neutralization by convalescent human sera, suggesting that some humans induce a narrow repertoire of neutralizing antibodies. By comparing the antibody-mediated mutational landscape in S protein with sequence variation in circulating SARS-CoV-2 strains, we identified single amino acid substitutions that could attenuate neutralizing immune responses in some humans.Competing Interest StatementM.S.D. is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals, and on the Scientific Advisory Board of Moderna and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. The Ellebedy laboratory has received unrelated funding support in sponsored research agreements from Emergent BioSolutions and funding support in sponsored research agreement from Abbvie to further develop 2B04 and 2H04 as therapeutic mAbs. A.H.E. and Washington University have filed a patent application that includes the SARS-CoV-2 antibodies 2B04 and 2H04 for potential commercial development. S.P.J.W. and Z.H.L have filed a disclosure with Washington University for VSV-SARS-CoV-2 mutants to characterize antibody panels. S. P. J. W has received unrelated funding support in sponsored research agreements with Vir Biotechnology and Abbvie.